Clinical Trial: Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.

Brief Summary: At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment failure rates with one week first line clarithromycin based triple therapy necessitating salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact duration of bismuth based second line treatment is not determined. Therefore, the investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple regimen as a second-line therapy.

Detailed Summary:
Sponsor: Asan Medical Center

Current Primary Outcome: Whether the two week group yield a higher eradication rate comparing to the one week group. [ Time Frame: At least four week after completion of treatment ]

Original Primary Outcome: Same as current

Current Secondary Outcome: side effect [ Time Frame: four weeks after completion of medication ]

Original Secondary Outcome: Same as current

Information By: Asan Medical Center

Dates:
Date Received: February 10, 2009
Date Started: June 2008
Date Completion:
Last Updated: December 4, 2016
Last Verified: December 2016